Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report

Daanen, Robin A.; Maas, Rutger; Koornstra, Rutger H.T.; Steenbergen, Eric J.; Herpen, Carla M.L. van; Willemsen, Annelieke E.C.A.B.

doi:10.1097/cji.0000000000000189

Cited by 61 publications

(45 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[82][83][84][85][86][87] Retrospective analyses and case reports describe the use of mycophenolate in the management of steroid-refractory irAEs, including those involving the liver, kidney, pancreas, and eyes. 43,[88][89][90][91] Intravenous immunoglobulin (IVIG) has been used to suppress a wide array of autoimmune and chronic inflammatory conditions. 92,93 It is comprised of pooled immunoglobulin G harvested from the plasma of healthy blood donors and prepared for intravenous administration.…”

Section: Immunomodulatorsmentioning

confidence: 99%

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson

Schneider

Brahmer

et al. 2019

Journal of the National Comprehensive Cancer Network

436

332

View full text Add to dashboard Cite

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

show abstract

Section: Immunomodulatorsmentioning

confidence: 99%

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson

Schneider

Brahmer

et al. 2019

Journal of the National Comprehensive Cancer Network

436

332

View full text Add to dashboard Cite

show abstract

“…with CPI therapy, five studies noted an overall pooled relative (Table 3); however, several others have also been described. 55,[57][58][59][60][61][62][63][64] On the basis of abstracts and unpublished data, however, the incidence of nephrotoxicity may be rising (9.9%-29%). 65 Two patients with granulomatous AIN complicating ipilimumab therapy were reported in 2014.…”

Section: Aki and Electrolyte Disordersmentioning

confidence: 99%

“…57,60 Finally, although AIN is by far the most common nephrotoxicity of CPI therapy, patients with immune complex GN, MCD, FSGS, and TMA have also been reported (Table 3). 55,57,[62][63][64][69][70][71] Kidney Transplantation Rejection CPI therapy in patients with kidney transplants and cancer raises concern for development of rejection. Current literature notes kidney rejection in one of three patients exposed to ipilimumab alone and eight of 14 rejection episodes with PD-1 inhibitor therapy.…”

Section: Aki and Electrolyte Disordersmentioning

confidence: 99%

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Perazella

Shirali

2018

JASN

131

108

View full text Add to dashboard Cite

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical practice, such that the subfield of "onco-nephrology" has emerged. Conventional chemotherapeutic drugs and novel agents targeting specific genes/proteins are effective cancer therapies but suffer from a number of adverse kidney effects. An effective avenue of cancer treatment is immunotherapy, which uses drugs that augment immune system-mediated recognition and targeting of tumor cells. As such, leveraging the immune system to target malignant cells represents an important modality in eradicating cancer. IFN and high-dose IL-2 are older immunotherapies used in clinical practice to treat various malignancies, whereas new cancer immunotherapies have emerged over the past decade that offer even more effective treatment options. The immune checkpoint inhibitors are an exciting addition to the cancer immunotherapy armamentarium. Chimeric antigen receptor T cells are also a new immunotherapy used to treat various hematologic malignancies. However, as with the conventional and targeted cancer agents, the immunotherapies are also associated with immune-related adverse effects, which includes nephrotoxicity.

show abstract

“…84,85 There also have been case reports of focal segmental glomerulosclerosis, Goodpasture disease, and IgA nephropathy associated specifically with the use of nivolumab. [51][52][53][86][87][88] Lupus-like nephritis also has been reported with anti−CTLA-4 blockade. 89…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 90%

Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma

Jaimes

2020

Seminars in Nephrology

View full text Add to dashboard Cite

Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report

Cited by 61 publications

References 9 publications

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma

Contact Info

Product

Resources

About